InvAscent, a pharma and healthcare-focused private equity firm, is in talks to exit its stake in Neuland Group, a contract research and manufacturing services (CRAMS) entity, said two people aware of the development, requesting anonymity as the talks are private.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
